Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma

REFERENCES

• Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211.
   PubMed Web of Science ®Google Scholar
• Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res. 2012;18(9):2423–2428.
   PubMed Web of Science ®Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. The Lancet Oncol. 2008;9(3):247–256.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334.
   PubMed Web of Science ®Google Scholar
• Yancey A, Harris MS, Egbelakin A, et al. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59(1):144–148.
   Google Scholar
• D’Aguanno S, D’Alessandro A, Pieroni L, et al. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation. J Proteome Res. 2011;10(2):416–428.
   Google Scholar
• Chen Y, Tsai Y-H, Fang Y, Tseng S-H. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg. 2012;47(10):1797–1805.
   Google Scholar
• Beaty O 3rd, Berg S, Blaney S, et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010;55(3):440–445.
   PubMed Web of Science ®Google Scholar
• Hellberg V, Wallin I, Eriksson S, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst. 2009;101(1):37–47.
   Google Scholar
• Riccardi A, Ferlini C, Meco D, et al. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 1999;35(1):86–90.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947.
   PubMed Web of Science ®Google Scholar
• Mascarenhas L, Malogolowkin M, Armenian SH, et al. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. Pediatr Blood Cancer. 2013;60(7):1103–1107.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24(3):500–506.
   PubMed Web of Science ®Google Scholar
• Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35(5):337–347.
   PubMed Web of Science ®Google Scholar
• London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286–3292.
   PubMed Web of Science ®Google Scholar
• London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010;28(24):3808–3815.
   Google Scholar
• Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29(2):208–213.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Modak S, Kramer K, et al. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2013;119(3):665–671.
   Google Scholar
• Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25(9):1054–1060.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98(11):2488–2494.
   PubMed Web of Science ®Google Scholar
• Valteau-Couanet D, Le Deley MC, Bergeron C, et al. Long-term results of the combination of the N7 induction chemotherapy and the Busulfan-Melphan high dose chemotherapy. Pediatr Blood Cancer. 2014;61:977–981.
   PubMed Web of Science ®Google Scholar
• Tebbi CK., London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin. Oncol., 2007;25(5):493–500.
   PubMed Web of Science ®Google Scholar
• Seif AE, Walker DM, Li Y, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer. 2014, Mar 26. doi: 10.1002/pbc.25043. [Epub ahead of print]
   Google Scholar
• Walker DM, Fisher BT, Seif AE, et al. “Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database.” Pediatr Blood Cancer. 2013;60(4):616–620.
   PubMed Web of Science ®Google Scholar